免疫球蛋白轻链淀粉样变性:2018年诊断、预后和治疗更新
免疫球蛋白轻链淀粉样变性是一种克隆性非增殖性浆细胞病,免疫球蛋白轻链或重链片段沉积于组织。诊断需刚果红染色显示苹果绿双折射,85%患者可通过骨髓、唾液腺或皮下脂肪抽吸发现淀粉样沉积。预后基于NT-proBNP、肌钙蛋白T和游离轻链差值分为四组,中位生存分别为94.1、40.3、14.0和5.8个月。治疗首选干细胞移植但仅20%符合条件,不适合移植者可选择美法仑-地塞米松或环磷酰胺-硼替佐米-地塞米松,达雷妥尤单抗似高度有效。
要点
- 组织活检刚果红染色见苹果绿双折射是诊断必需,且必须验证淀粉样物为免疫球蛋白轻链。
- NT-proBNP、肌钙蛋白T和游离轻链差值将患者分为四组,中位生存分别为94.1、40.3、14.0和5.8个月。
- 干细胞移植是首选但仅20%患者符合条件;不移植者可选美法仑-地塞米松或环磷酰胺-硼替佐米-地塞米松。
核心结论
- 延迟诊断仍是启动有效治疗的主要障碍。
研究设计与样本
- 本文为2018年关于免疫球蛋白轻链淀粉样变性诊断、预后和治疗的更新综述。
主要发现
- 骨髓、唾液腺或皮下脂肪抽吸可在85%的患者中发现淀粉样沉积。
- NT-proBNP、血清肌钙蛋白T及受累与未受累免疫球蛋白游离轻链差值将患者分为四组,中位生存分别为94.1、40.3、14.0和5.8个月。
- 仅20%的患者符合干细胞移植条件。
- 达雷妥尤单抗在AL淀粉样变性中似高度活跃。
关键数值与推荐
- 诊断需组织活检刚果红染色显示淀粉样沉积伴苹果绿双折射。
- 验证淀粉样物由免疫球蛋白轻链构成的金标准是激光捕获质谱法。
- 安全干细胞移植的要求包括收缩压>90 mm Hg、肌钙蛋白T<0.06 ng/mL、年龄<70岁及血清肌酐≤1.7 mg/dL。
- 不适合移植的候选者可接受美法仑-地塞米松或环磷酰胺-硼替佐米-地塞米松。
临床怎么用
- 所有系统性淀粉样变性综合征患者均需治疗以预防淀粉样物沉积于其他器官并防止进行性器官衰竭。
- 干细胞移植是首选,但仅20%的患者符合条件。
- 不适合移植的候选者可接受美法仑-地塞米松或环磷酰胺-硼替佐米-地塞米松。
- 达雷妥尤单抗在AL淀粉样变性中似高度活跃。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and "atypical multiple myeloma." DIAGNOSIS: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple-green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow, salivary gland, or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. The gold standard is laser capture mass spectroscopy. PROGNOSIS: N-terminal pro-brain natriuretic peptide (NT-proBNP), serum troponin T, and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months. THERAPY: All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include systolic blood pressure >90 mm Hg, troponin T < 0.06 ng/mL, age < 70 years, and serum creatinine ≤1.7 mg/dL. Nontransplant candidates can be offered melphalan-dexamethasone or cyclophosphamide-bortezomib-dexamethasone. Daratumumab appears to be highly active in AL amyloidosis. Antibodies designed to dissolve existing amyloid deposits are under study. FUTURE CHALLENGES: Delayed diagnosis remains a major obstacle to initiating effective therapy. EDUCATIONAL OBJECTIVES: Upon completion of this educational activity, participants will be better able to: Master recognition of clinical presentations that should raise suspicion of amyloidosis. Understand simple techniques for confirming the diagnosis and providing material to classify the protein subunit. Recognize that a tissue diagnosis of amyloidosis does not indicate whether the amyloid is systemic or of immunoglobulin light chain origin. Understand the roles of the newly introduced chemotherapeutic and investigational antibody regimens for the therapy of light chain amyloidosis.
引用
- Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018. PMID: 30040145. doi:10.1002/ajh.25149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。